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ABSTRACT
Histone Deacetylase 6 (HDAC6) Is Critical for Tumor Cell Survival
and Promotes the Pro-Survival Activity of 14-3-3ζ via
Deacetylation of Lysines Within the
14-3-3ζ Binding Pocket
Jeffrey Benjamin Mortenson
Department of Chemistry and Biochemistry, BYU
Master of Science
Our understanding of non-histone acetylation as a means of cellular regulation is in its
infancy. Using a mass spectrometry approach we identified acetylated lysine residues and
monitored acetylation changes across the proteome as a consequence of metabolic stress (hypoxia).
We observed changes in acetylation status of non-histone lysines in tumor cells. Through the use
of small molecule inhibitors of histone deacetylase enzymes (HDACs) and siRNA screening
identified HDAC6 as a pro-survival regulator of lysine acetylation during hypoxia.
The phospho-binding protein 14-3-3ζ acts as a signaling hub controlling a network of
interacting partners and oncogenic pathways. We show here that lysines within the 14-3-3ζ binding
pocket and protein-protein interface can be modified by acetylation. The positive charge on two
of these lysines, K49 and K120, is critical for coordinating 14-3-3ζ-phosphoprotein interactions.
Through screening, we identified HDAC6 as the K49/K120 deacetylase. Inhibition of HDAC6
blocks 14-3-3ζ interactions with two well-described interacting partners, Bad and AS160, which
triggers their dephosphorylation at S112 and T642, respectively. Expression of an acetylationrefractory K49R/K120R mutant of 14-3-3ζ rescues both the HDAC6 inhibitor-induced loss of
interaction and S112/T642 phosphorylation. Furthermore, expression of the K49R/K120R mutant
of 14-3-3ζ inhibits the cytotoxicity of HDAC6 inhibition. These data demonstrate a novel role for
HDAC6 in controlling 14-3-3ζ binding activity.
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CHAPTER 1: INTRODUCTION
The health of the overall organism depends on the ability of each individual cell to carry out its
necessary functions. For a cell to function properly in this context, it must sense environment cues
and communicate these to gene expression machinery within the nucleus via cell signaling
pathways. As such, cellular pathways are tightly regulated to ensure proper functionality within
the scope of the good of the entire organism. The deregulation of cellular pathways can have
serious consequences to the organism including the development of cancer and degenerative
diseases. These cell signaling pathways are controlled in large part by the addition (and removal)
of post-translational modifications (PTMs) to proteins within the pathway. The best studied PTM
is the addition and removal of phosphate groups to serine, threonine, and tyrosine residues. Other
modifications have gained interest in more recent years due to our understanding of their scope
and importance to cellular regulation. My thesis focuses on understanding a relatively poorly
understood PTM, lysine acetylation, and its impact on the function of the critical cell signaling
regulator 14-3-3ζ.
Lysine residues are subjected to a variety of PTMs. The dynamic addition and removal of
methyl groups, ubiquitin groups, poly-ubiquitin groups, glycosyl groups, and lipid groups are
under investigation for their role in modulating the function of the protein they decorate (1,2,3).
Acetylation, another lysine modification, has received increasing attention recently for its role in
protein regulation. The addition of an acetyl group on the free ε-amino group of lysine residues is
carried out by cellular enzymes known as histone acetyltransferases (HATs). HATs are
ubiquitously expressed in all higher order eukaryotes and have long been known to catalyze the
addition of acetyl groups to free lysine residues of histone proteins, thus the name (4). Free amino
groups on lysine side chains hold a positive electrostatic charge; this charge can be very important
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to the conformational state and electrostatic properties of the protein, thus playing a role in protein
function (5). An acetyl group neutralizes the charge of the lysine side chain potentially resulting
in a local change in electrostatic properties around the modified lysine residue.
The removal of acetyl groups on modified lysine residues is performed by histone
deacetylases (HDACs), which catalyze the hydrolysis of the acetyl groups producing a free amino
groups once again. HDACs have been extensively investigated in their role in deacetylating
histone proteins in the nucleus and other chromatin remodeling proteins involved in gene
expression (6,7). The designation “histone” deacetylase, or “histone” acetyltransferase could be
considered a misnomer due to the more recent investigative insight into the extent of acetylation
throughout the cell, not only restricted to the nucleus (8,9,10). One could more generally categorize
these enzymes as lysine deacetylases, or KDACs. Recently several ground breaking studies have
been undertaken to understand the extent of acetylation on a proteomic scale (8,9,10). Mattias
Mann’s group and others have used large scale mass spectrometric approaches to determine that
there are hundreds of different cytosolic and mitochondrial targets of acetylation, also that changes
in cellular environment, nutrient availability, or HDAC inhibition can have large changes on
acetylome patterns.
During tumorigenesis and cancer progression tumor cells become primarily glycosidic and
must maintain growth and survival under stressful conditions (11). Solid tumors experience
periods of low blood flow resulting in regions of the tumor being subjected to hypoxia and low
glucose. Given the fact that tumor hypoxia is a clinical indicator for poor patient prognosis (12),
tumor hypoxia could potentially select for tumor cells well adapted to survival and progression
under metabolically difficult circumstances. This could allow these cells to go on to seed other
lethal tumors. Some evidence (described in more detail in chapter 3) suggests that acetylation could
2

play a role in tumorigenesis and the ability of cancer cells to maintain high glycolysis and runaway growth. This is apparent in the many current clinical trials investigating general and specific
HDAC inhibitors alone or in combination with other chemotherapy drugs as a means to treat
various cancers (13).
Histone deacetylase 6 (HDAC6) is one such drug target that has been specifically targeted
using small molecule inhibitors in cancer. HDAC6 is overexpressed in several cancer types (14)
and is found primarily in the cytosol closely associated with the cytoskeleton. Indeed HDAC6 has
been shown to directly deacetylate alpha-tubulin which promotes cytoskeletal stability (15).
HDAC6 has been shown to be important in its role in promoting the unfolded protein response
which is important to cell survival under stress conditions (16). HDAC6 has few known protein
targets, which highlights the importance of finding targets for its deacetylase activity that could
help to explain the oncogenic role of HDAC6. Further study of oncogenic acetylation regulation
occurring in the cytosol has become an important question and one that will be addressed in this
thesis.
The protein 14-3-3ζ is one such cytosolic protein that we have found to be regulated by
acetylation pathways. 14-3-3ζ is one of seven isoforms of the 14-3-3 family of proteins. 14-3-3s
have no known enzymatic properties but function by binding to other cellular proteins thereby
modulating those proteins in a variety of different ways. 14-3-3s form homo- or heterodimers with
other isoforms of 14-3-3 and bind to one or multiple proteins at the same time. 14-3-3 binds to
phosphorylated proteins via interactions between positively charged amino acids (including
lysines) within its binding pocket and the negatively charged phosphate of the binding partner. 143-3s are ubiquitously expressed in all eukaryotes and in all tissues being highly conserved between
different isoforms and from different species. It has been suggested that because of the several
3

different genes for 14-3-3s that there is some functional specificity for the various isoforms of the
protein. How much of each isoforms function overlaps with other isoforms is not known, though
the formation of functional heterodimers suggests some overlap (17).
14-3-3ζ is a protein that generally promotes a pro-survival, pro-growth phenotype (18).
Indeed 14-3-3ζ is overexpressed in many different types of cancer (19), and as will be shown in
this work, 14-3-3ζ is more highly expressed in more aggressive breast cancer types. 14-3-3ζ exerts
this phenotype by binding to and modulating the activity of critical proteins involved in apoptosis,
cell cycle, and other cell fate determining pathways (20). It has been known for some time that the
ability of 14-3-3ζ to bind to its target protein is usually determined by the phosphorylation status
of the serine/threonine on the target protein binding motif (5). In this way 14-3-3ζ can be thought
to act as a logic gate requiring the input of a kinase to allow 14-3-3ζ to complete its function (21).
This type of phosphorylation regulation is well known and is ubiquitous in cell biology. Though,
as has been previously stated, we have increased our understanding of the scope and importance
of other PTM modifications, such as acetylation, in regulating cytosolic pathways. It has become
increasingly important to develop better tools to better understand these complexities in protein
regulation. Fortunately researchers have become highly skilled in analyzing protein lysine
acetylation using mass spectrometry (7,8,9). With our improving methods and tools, it is becoming
possible to screen complex cellular mixtures to monitor acetylation status. Analyzing the
acetylation changes that occur during tumor formation has become an important question in how
a cell might attain the necessary biochemical changes for tumor growth. Furthermore, if these
pathways can be elucidated specific drug combinations may be developed to target cancer
pathways on many fronts.

4
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CHAPTER 2: HDAC6 IS NECESSARY FOR TUMOR CELL SURVIVAL DURING
HYPOXIA

INTRODUCTION
Protein lysine acetylation is a reversible posttranslational modification (PTM) that is
regulated by the activity of lysine acetyl-transferases (KATs) and lysine deacetylases (KDACs).
Although acetylation approaches protein phosphorylation in terms of its scope across the proteome
(1), our understanding of the mechanisms by which acetylation modulates cellular pathways is
limited. Numerous in vitro studies targeting KDAC activity in cancer implicate lysine acetylation
pathways in cell survival signaling (reviewed in (2)). Furthermore, the use of KDAC inhibitors in
human cancer trials to enhance chemotherapy-induced tumor cell death implicate KDAC activity
and protein acetylation as modulators of cell survival pathways in vivo. KDACs can be categorized
based on their nuclear, cytosolic or mitochondrial localization. While the pro-survival function of
nuclear KDACs is attributed to their modulation of histone acetylation and gene expression, the
cytosolic and mitochondrial expression of several pro-survival KDACs and the high frequency of
acetylation on cytosolic and metabolic proteins suggest that lysine acetylation may also regulate
cell fate by modulating non-histone proteins and pathways (3-6).
Studies in both prokaryotes and mammalian cells suggest that changes in carbon source
alter protein acetylation (3,5,7), which in turn can affect protein activity via several mechanisms,
including allosteric regulation, direct interference with an enzyme’s active site, or modulation of
protein degradation (reviewed in (6)). In this sense, acetylation seems to be akin to other betterunderstood PTMs like phosphorylation in its ability to alter protein function in a variety of ways.
Importantly, however, acetyl-CoA levels can be limiting for certain acetylation events (on histones
for example), such that the level of protein acetylation tracks with acetyl-CoA levels (7,8). Indeed,
7

simply adding citrate to increase the cellular acetyl-CoA pool is sufficient to modulate protein
acetylation and affect cell survival (7,9). Thus, the link between metabolic conditions, acetyl-CoA
production, and changes in acetylation suggest that acetylation fits within a class of metabolitederived PTMs (including lipidation and glycosylation) that may function as sensors to modulate
core cellular pathways in response to changing nutrient levels.
Given the growing body of data implicating non-histone acetylation and cytosolic KDACs
in metabolism and cell survival, we became interested in identifying pathways and mechanisms
by which non-histone acetylation modulates cell survival. We chose to pursue these studies in the
context of hypoxic stress (defined here as low glucose and low oxygen) given its frequent
occurrence within solid tumors and its role in promoting chemoresistance (10). Using an acetylproteomics approach, we identified acetylation events across the proteome that changed
dynamically under hypoxic conditions. Blunt perturbation of acetylation pathways with a KDAC
inhibitor sensitized cells to hypoxia and further RNAi screening of all known human KDACs and
KATs revealed specific modulators of cell fate in hypoxia. Prominent among the most significant
hits in this screen was HDAC6, a cytosolic microtubule-associated deacetylase that regulates a
variety of processes important to human disease, including cell survival, gluconeogenesis, cancer
metastasis, and proteotoxicity (reviewed in (11)). For this reason, HDAC6 has recently emerged
as a potential therapeutic target in cancer (12) and neurodegenerative disease (13). We found that
inhibition of HDAC6, either via small molecule targeting or RNAi, potently sensitizes cells to
hypoxia.
EXPERIMENTAL PROCEDURES
Cell culture-MDA-MB-231, MDA-MB-435, HEK-293T, and U2OS cells were purchased
fro ATCC. All cell lines were maintained under sterile conditions using high glucose Dulbecco’s
8

Cell culture-MDA-MB-231, MDA-MB-435, HEK-293T, and U2OS cells were purchased
from ATCC. All cell lines were maintained under sterile conditions using high glucose Dulbecco’s
modified Eagle’s Medium (DMEM purchased from Gibco) supplemented with 10% fetal bovine
serum and 2 mM glutamine. The cells were cultured at 37C in 5% CO2/air. For all hypoxia
treatments, cells were cultured in glucose-free DMEM (Gibco) supplemented with 2 mM glucose
and cultured in a sterile hypoxia incubator at 37C in 5% CO2/air and 1% O2.
Acetyl-proteomics and data analysis-Samples for acetyl-proteomics were generated by
solubilization of cellular proteins, tryptic digestion, enrichment of acetyl-lysine (Kac) peptides,
and LC-MS/MS analysis similar to previously described, with the exception that a pan-acetylK
antibody (#11786BK) from Cell Signaling Technologies was utilized for the IP (20). Care was
taken that the temperature not exceed 32°C throughout the procedure, to limit protein
carbamylation by Urea. Briefly, samples were solubilized in 50 mM Ammonium Bicarbonate
(AmBic, pH 8) containing 8 M Urea, then normalized to total protein content across all samples
using a Bradford assay (Bio-Rad, Inc). The samples were reduced with 10 mM dithiothreitol at
32°C for 1 hr, followed by alkylation with 40 mM iodoacetamide for 1 hr in the dark. Samples
were diluted to 1.8 M Urea with AmBic, then sequencing grade trypsin was added at a 1:25 w/w
ratio and digestion proceeded overnight at 32°C. Samples were acidified to 1% TFA, buffer
exchanged with Sep Pak C18 (Waters) and lyophilized to dryness. Peptides were resuspended in
IAP Buffer (Cell Signaling Technologies) and incubated with a 40 ul aliquot of PTMScan AcetylK enrichment kit (11786BK) at 4C overnight. Enriched peptides were eluted with 1% TFA for 10
minutes, dried in a speed-vac, and resuspended in 12 ul 1/2/97 v/v/v TFA/MeCN/water containing
a total of 50 fmol ADH1_YEAST digest (Waters Corporation). LC-MS/MS analysis took place on
a nanoAcquity UPLC coupled via electrospray to a LTQ Orbitrap XL mass spectrometer exactly
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as previously described (20). Database searching for peptide identifications utilized Mascot v2.2
(Matrix Sciences), searching the Uniprot (‘reviewed’) database (www.uniprot.org) with homo
sapiens taxonomy, searching the data with 10 ppm precursor and 0.8 Da product ion tolerance,
and allowing for variable modifications deamidation (NQ), oxidation (M), and acetylation (K).
Quantitative data were processed in Rosetta Elucidator v3.3, allowing relative quantification of all
peptides identified in this dataset based on extracted ion chromatograms (peak areas) and accuratemass and retention time alignment.
SRB assays-For 14-3-3ζ expression via plasmid transfection, HEK-293T cells were plated
in 6-cm dishes at approximately 60% confluency. After transfection, cells were trypsinized and
plated in 96-well plates at 30% confluency. Cells were treated with Tubacin (ranged from 10 μM
to 80 μM) in combination with hypoxia (1% O2, 2 mM glucose) for 48 hours. MDA-MB-435 cells
were plated in 96-well plates at a density of 25% initial confluency before siRNA transfection.
After 24 hours of siRNA treatment, cells were treated with hypoxia for 48 hours. Following
hypoxia treatment, all 96-well plates were assayed using G Biosciences CytoScan SRB
Cytotoxicity Assay kit (G Biosciences, St. Louis, MO, USA) according to the manufacturer’s
protocol. Absorbance values for each treated well were normalized using control untreated wells
grown on the same plates. Cytotoxicity was calculated as 100*(Absorbance control - Absorbance
treated)/Absorbance control.
Flow cytometry-MDA-MB-435 or U2OS cells were initially plated in 6-well plates at 2030% confluence (20% for siRNA transfected cells and 30% for Tubacin treated cells). After 24
hours, cells were treated with either siRNA transfection followed by 48 hours of hypoxia, or 48
hours of a Tubacin (10 μM) and hypoxia combination treatment. HEK-293 cells were plated in 6cm dishes at a confluency of 75%. Cells were then transfected with HA-14-3-3ζ WT or RR mutant
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expression plasmid. HEK cells were then trypsinized and plated in 6-well plates at 30% initial
confluency followed by 48 hours of a Tubacin (10-40 μM) and hypoxia combination treatment.
Following treatment, the 6-well plates were prepared for flow cytometry analysis. Briefly, cells
were trypsinized then washed with cold PBS. Next, cells were resuspended in cold PBS with 0.2%
FBS and 1 µg/ml propidium iodide. Cells were analyzed for cell death using BD Facs Canto
system.
Western blotting-MDA-MB-231, MDA-435, U2OS, cells were plated in 6 well plates at
75% confluency followed by siRNA transfection or drug treatments. Cells treated with siRNA
HDAC6 knockdown were transfected with siRNA 12 hours after 14-3-3ζ transfection and allowed
to grow for 36 hours. Following drug treatment or siRNA transfection, cells were lysed in an icecold Amandas coIP buffer (10 mM HEPES pH 7.5, 150 mM KCl, 0.1% NP-40, 10 mM betaglycerophosphate, protease inhibitor cocktail). Cell lysates were centrifuged at 21000xg for 10
minutes, supernatant samples were boiled with SDS sample buffer (10% SDS, 30% glycerol, 0.7
M beta-mercaptoethanol, 0.15 M Tris, Bromophenol Blue). 40 µg of each sample was loaded and
separated on 10-12% polyacrylamide gels. Western blots were visualized on LiCor Odyssey
system (Lincoln, NE, USA).
Antibodies-Antibodies used: HDAC6 (#7612S) purchased from Cell Signaling Technology
(Beverly, MA, USA), Actin (sc-1616-R) purchased from Santa Cruz Biotechnology (Dallas, TX,
USA); HDAC1 provided by Dr. Srividya Bhaskara (University of Utah, USA).
siRNA and plasmid transfections-HEK-293 and U2OS cells were transfected with plasmid
expression vectors pcDNA3.1 HA-14-3-3ζ, HA-Atg9 (gift from Luigi Puglielli at the University
of Wisconsin using Turbofect transfection reagent and protocol (#R531, Thermo Scientific,
Rockford, IL, USA). MDA-MB-435, U2OS, and HEK-293 cells were transfected with smartpool
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siRNA from Dharmafect (Thermo Scientific, Rockford, IL, USA) using RNAiMax Lipofectamine
reagent and protocol (Invitrogen, Rockford, IL, USA).

RESULTS
Perturbation of acetylation dynamics sensitizes cells to metabolic stress-To gain a better
understanding of the underlying proteome-wide changes in acetylation occurring in hypoxia, we
pursued an acetyl-proteomics approach (1). Of note, “hypoxia” in our experiments refers to in vitro
conditions that mimic the ischemia commonly found within solid tumors, in which both oxygen
and glucose are limited. Three cell lines were chosen for analysis: MDA-MB-231s and MDA-MB435s, which we had previously characterized as being relatively sensitive and resistant,
respectively, to hypoxia-induced cell death. In addition, we chose HEK-293s as a third cell line
for comparison. Prior to proteomics analysis, cells were treated with hypoxia (1% O2, 2mM
glucose) for 3 hours or left in normoxia (atmosopheric O2, 20 mM glucose). Affinity purification
of acetylated peptides and LC-MS/MS analysis revealed approximately 658 different acetylation
sites, representing 303 acetylated proteins. Using label-free quantification to measure relative
abundance of these acetylated peptides under hypoxic or normoxic conditions across the three cell
lines, we found that HEK-293 cells showed the highest magnitude change in acetylation between
treatments, while MDA-MB-231 and MDA-MB-435 cells showed lower magnitude changes in
acetylation, respectively (Fig 1A). Replotting these data as a 2D hierarchical cluster across all
acetylated peptides and cell lines also shows the highest correlation in acetylation change between
hypoxic and normoxic cells first within a given cell line, then between MDA-MB-231 and MDAMB-435, then finally within HEK-293 cells. These changes are depicted in Figure 1C.
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1 Figure 1. Oxygen and glycose limitation induces changes in acetylation across the proteome. (A)

Acetyl-proteomic profiling was performed using MDA-MB-435, MDA-MB-231, and HEK293 cell lines.
Cells were incubated under normal cell culture conditions or treated with 2mM glucose and 1% O2 for three
hours. Acetyl-peptide intensities from all cell lines were quantified using Elucidator software, which is
represented as ratio dot plots (normoxic peak intensities on y-axis and correlating hypoxic peak intensities
on x-axis). (B) Data from all cell lines and treatments were replotted as a 2D hierarchical cluster. Labels of
1 and 2 represent different runs on the mass spectrometer. (C) Acetyl-peptides were categorized by parent
proteins using Panther GO annotation software and grouped according to biological activity and pathway.
(D) MDA-MB-435 breast cancer cells were treated with 100 nM SAHA or vehicle (DMSO) and normoxic
or hypoxic conditions (2mM glucose and 1% O2) for 48 hours. Cell death was measured by PI staining and
flow cytometry (mean±SEM, n=3).
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Further categorization of all acetyl-lysine peptides from the LC-MS/MS analysis according
to biological process showed that a large proportion of the targets were associated with nucleic
acid processing, core metabolic pathways, and protein metabolism (Fig 1B). A subset of cancerassociated proteins that showed a hypoxia-triggered change in acetylation is highlighted in Table
1. Given that MDA-MB-435s showed very little change in acetylation in hypoxia and appeared
relatively insensitive to hypoxic stress, we were interested in determining whether blunt
perturbation of acetylation pathways with a KDAC inhibitor (KDACi) could sensitize these cells
to hypoxia. MDA-MB-435 cells were treated with the pan-KDACi suberoylanilide hydroxamic
acid (SAHA) at low concentrations to minimize off-target effects of the drug. Under these
conditions, we observed a significant increase in hypoxia-induced death in SAHA-treated cells
(Fig 1D) with very low toxicity in normoxic cells, suggesting that interfering with acetylation at
the level of acetylation turnover sensitizes cells to hypoxia.
Table 1. Summary of selected acetylated lysine peptides. A subset of proteins that displayed changes
in acetylation under hypoxic conditions. Lysine position, acetylation intensity fold change in hypoxia, and
other known PTMs are shown.
1

Screening reveals HDAC6 as a regulator of cell survival in hypoxia-Given these results,
we became interested in identifying specific acetylation-regulating enzymes that modulate cell
survival under conditions of metabolic stress. Therefore we used an RNAi screening approach in
14

which MDA-MB-435 cells were transfected with siRNA from a custom library targeted against
*

*

*

2 Figure 2. RNAi screen identifies acetylation-regulating enzymes required for cell survival in

hypoxia. (A) MDA-MB-435 breast cancer cells were transfected with 75 nM siRNA against all human
KATs and KDACs (custom smart pool library, Dharmacon), followed by exposure to hypoxia for 48 hours.
Total cellular content was measured using absorbance-based SRB assay. Cytotoxicity (% vs. control) was
calculated against mock-treated cells (mean±SEM, n=3, *indicates p-value<0.05). (B) Representative
Western blot of HDAC6 knockdown using siRNA from library. Numbers below blots represent the
intensity of HDAC6 normalizd to Actin as quantified by LI-COR infrared imaging. (C) Representative
immunoblot of HDAC1 knockdown using siRNA from library. Bands were quantified as in panel B. (D)
MDA-MB-435 cells were transfected with smartpool HDAC1 siRNA or scrambled siRNA and exposed to
normoxic or hypoxic conditions for 48 hours. Cell death was measured by PI staining and flow
cytometry. Data represented as bar graph (mean±SEM, n=3), or (E) Light microscope images.
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which MDA-MB-435 cells were transfected with siRNA from a custom library targeted against
known human KDACs and KATs, followed by hypoxia treatment and measurement of cell
viability. For our initial assessment of viability we used an SRB cytotoxicity assay, which
measures cellular content in each well. Follow-up assays using propidium iodide staining and flow
cytometry to quantify cell death were used to validate selected hits. Four separate experiments are
summarized in Figure 2A. Several KDAC-targeted siRNAs caused a significant decrease in cell
viability, with depletion of HDAC4, HDAC6 and Sirt3 showing the highest magnitude cytotoxicity
in the screen (Fig 2A). The HDAC4 and Sirt3 results are corroborated by published studies
showing that HDAC4 positively regulates HIF-1a activation (22), and Sirt3 is required for cell
survival in hypoxia (23). Figures 2D, E and 3A show further validation of HDAC1 and HDAC6
as pro-survival factors in hypoxia. Consistent with the SRB data in Figure 2A, Depletion of
HDAC1 had a moderate effect on cell survival in hypoxia (Fig 2D,E), while depletion of HDAC6
potently enhanced hypoxia-induced cell death (Fig 3A-D). Further targeting of HDAC6 with the
selective inhibitor Tubacin sensitized both MDA-MB-435s and the osteosarcoma cell line U20S
to hypoxia-induced death (Fig 3E-G). Taken together, these data suggest that perturbation of
lysine acetylation pathways via selective inhibition of individual deacetylases, including the nonhistone deacetylase HDAC6, sensitizes cells to metabolic stress.
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3 Figure 3. Inhibition of HDAC6 sensitizes cells to hypoxia. (A) MDA-MB-435 cells were transfected

with 75 nM smartpool HDAC6 siRNA or scrambled siRNA and exposed to normoxic or hypoxic conditions
for 48 hours. Cell death was measured by PI staining and flow cytometry. Data represented as light
microscope pictures, or (B) Bar graph (mean±SEM, n=3), or (C) Flow cytometry dot plots. (D) U2OS cells
were transfected with smartpool 75 nM HDAC6 siRNA or scrambled siRNA and exposed to normoxic or
hypoxic conditions for 48 hours. Cell death was measured by PI staining and flow cytometry. Data
represented as bar graph (mean±SEM, n=3), or (E) Light microscope pictures. (F) MDA-MB-435 cells
were treated with a combination treatment of tubacin (10 μM) or vehicle and normoxic or hypoxic
conditions for 48 hours. Cell death was measured by PI staining and flow cytometry. Data from three
replicate experiments is presented as a bar graph (mean±SEM, n=3). (G) U2OS cells were treated in same
manner as in figure 3F. Cell death was measured by PI staining and flow cytometry. Data represented as
bar graph (mean±SEM, n=3).
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DISCUSSION
While the acetylation of histones was discovered nearly a half century ago (31), the
occurrence of acetylation on non-histone proteins has been a relatively recent finding (32). The
rapid development and improvement of acetyl-proteomics methodologies within the last 6 years
has led to the discovery of hundreds of acetylated proteins across the mitochondrial and cytosolic
proteomes (1,3,5). In addition, the last decade has brought a greater understanding of the diversity
within the HDAC and Sirtuin deacetylase families, revealing several deacetylases that primarily
regulate non-histone substrates. These include Sirt2, Sirt3 (a mitochondrial deacetylase), HDAC6
and HDAC10. Furthermore, HDACs and Sirtuins initially thought to be strictly nuclear
deacetylases (e.g., HDAC3, HDAC4 and Sirt1) have been shown to shuttle between the nucleus
and cytoplasm and target non-histone proteins (reviewed in (33)). However, the functional
consequences of non-histone acetylation remain poorly understood.
Two lines of evidence motivated us to look at acetylation dynamics in the context of low
glucose/oxygen metabolic stress. First, changes in carbon source have been shown to modulate
acetylation levels of non-histone proteins (3,5). Second, the manipulation of acetyl-CoA levels,
which is known to affect protein acetylation (7,8), has been shown to modulate core regulators of
cell survival (9). Based on these data, we posited that acetylation-regulated pathways might play
a critical role in survival under conditions that mimic tumor hypoxia, in which cells are forced to
shift their metabolism from glucose to alternative carbon sources (34). Indeed, our acetylproteomics studies revealed changes in acetylation in response to hypoxia, and perturbation of
acetylation turnover via KDAC inhibition sensitized cells to hypoxia-induced death. Interestingly,
while we observed a slight trend toward an overall decrease in acetylation in hypoxic cells, many
lysines showed increased acetylation—suggesting that changes in acetylation under these
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conditions are not simply a function of acetyl-CoA levels, but may reflect changes in KAT and/or
KDAC activity. Together, our data demonstrate that the activity of HDAC6 is critical for
suppressing cell death under conditions of metabolic stress.
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CHAPTER 3: HISTONE DEACETYLASE 6 (HDAC6) PROMOTES THE PRO-SURVIVAL
ACTIVITY OF 14-3-3ζ VIA DEACETYLATION OF LYSINES WITHIN THE 14-3-3ζ
BINDING POCKET

INTRODUCTION
The 14-3-3 protein family includes seven human isoforms that regulate diverse processes,
including metabolism, cell cycle control, protein trafficking, cell motility, and apoptosis. While
these functions are somewhat dispersed between the different isoforms, the zeta (ζ) isoform plays
a prominent role in promoting cell growth and survival pathways (1). Like other 14-3-3 isoforms,
14-3-3ζ functions by binding to and modulating the activity of a large network of serine/threoninephosphorylated proteins. Depending on the phosphorylated protein in question, the effect of 14-33ζ binding varies from activation, suppression, sequestration, or scaffold-like activity.
14-3-3ζ coordinates the activation of several well-characterized oncogenic, metabolic, and
pro-survival pathways. For example, in response to insulin, 14-3-3ζ binds to the AKTphosphorylated GTPase protein AS160. This insulin-dependent binding event promotes
translocation of the glucose transporter GLUT4 to the plasma membrane (2). Once inserted into
the membrane, GLUT4 is active and supports Warburg metabolism and proliferation in breast
cancer and multiple myeloma (3-5). As another example, in response to glucose, 14-3-3ζ interacts
with and suppresses Bad, a critical BH3-only protein required for chemotherapy-induced apoptosis
(6-9). 14-3-3ζ expression also promotes epithelial to mesenchymal transition (EMT) by
cooperating with HER2 in breast cancer (10), enhances anchorage-independent growth (11,12),
and suppresses anoikis (12). Many of these phenotypes have been attributed to 14-3-3ζ-mediated
regulation of the TGF-β/Smads, IGF1R, PI3K/AKT, and β-catenin pathways (reviewed in (13)).
Furthermore, 14-3-3ζ interacts with and suppresses both Caspase-2 (14,15) and the Forkhead
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family member FKHRL1, preventing the expression of the pro-apoptotic Bax and Fas proteins
(16).
Clinical studies demonstrate a correlation between high 14-3-3ζ expression and poor
prognosis in several cancer types, including lung, head and neck, glioblastoma, and breast cancer
(10-13,17,18). Furthermore, Bergamaschi et al. demonstrated that high 14-3-3ζ expression is
positively correlated with breast tumor relapse, metastasis, tamoxifen treatment, and tamoxifen
resistance (19). Moreover, we show here that 14-3-3ζ expression is particularly high in the more
aggressive breast cancer subtypes and in tumors with negative receptor status. In support of an
oncogenic function for 14-3-3ζ, others have shown that the depletion of 14-3-3ζ suppresses
proliferation and enhances chemosensitivity in xenografted breast tumors (10,11). Based on this
rationale, several groups have attempted to develop 14-3-3ζ inhibitors (reviewed in (20,21),
Andersen unpublished), but no 14-3-3ζ-directed therapeutic strategies are currently being used in
the clinic.
The current paradigm of 14-3-3ζ regulation states that 14-3-3ζ interactions depend
primarily on the serine/threonine phosphorylation of binding partners—thus, phosphorylation of
binding partners is considered a major determinant of 14-3-3ζ binding activity. Comparatively
little is known about other potential determinants of 14-3-3ζactivity (22-25). In search of posttranslational modifications that regulate 14-3-3ζ directly, we identified several lysines on 14-3-3ζ
that are modified by acetylation. Lysine-to-glutamine (K-to-Q) mutations at two of these lysines,
K49 and K120, abolish 14-3-3ζ binding activity. In an effort to modulate 14-3-3ζ binding via
acetylation, we developed site-specific antibodies to both acetyl-K49 and acetyl-K120 and
identified HDAC6 as the 14-3-3ζ-targeted deacetylase.
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Recent studies implicate HDAC6 as a therapeutic target in cancer (26-29), and our data
suggest that HDAC6 inhibition may provide a means to inhibit 14-3-3ζ. Toward this end, we show
that inhibition of HDAC6 triggers dissociation of 14-3-3ζ from AS160 and Bad, two wellcharacterized binding partners. We also show that these dissociation events lead to decreased
AS160 T642 and Bad S112 phosphorylation. Importantly, the loss of interaction and
phosphorylation due to HDAC6 inhibition is rescued by an acetylation-refractory lysine-toarginine (K-to-R) mutant of 14-3-3ζ. Together, our data suggest a model in which 14-3-3ζ activity
is governed by the balance between K49/K120-targeted deacetylase activity and acetyl-transferase
activity. We posit that under normal growth conditions, 14-3-3ζ acetylation is maintained at a very
low level by HDAC6, allowing deacetylated 14-3-3ζ to bind and modulate its network of
interacting proteins. However, upon HDAC6 inhibition, acetylation of 14-3-3ζ promotes
dissociation of 14-3-3ζ-protein complexes, resulting in a loss of 14-3-3ζ-mediated growth and
survival signaling.

EXPERIMENTAL PROCEDURES
Cell culture and reagents – MDA-MB-231, HEK-293T, and U2OS cells were purchased
from ATCC. All cell lines were maintained under sterile conditions using high glucose Dulbecco’s
modified Eagle’s medium (DMEM; purchased from Gibco) supplemented with 10% fetal bovine
serum and 2 mM glutamine. The cells were cultured at 37C in 5% CO2/air. HDAC inhibitor drugs
SAHA, Trichostatin A, Salermide, Ex-527, Tubacin, and Tubastatin A were purchased from
Cayman Chemical (Ann Arbor, Michigan, USA). Drugs applied to cell culture were first dissolved
in DMSO and then added to culture media to the final concentrations indicated.
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siRNA and plasmid transfections – HEK-293T and U2OS cells were transfected with
plasmid expression vectors pcDNA3.1 HA-14-3-3ζ HA-Atg9 (gift from Dr. Luigi Puglielli at the
University of Wisconsin), FLAG-AS160 (gift from Dr. Gus Lienhard at Dartmouth University),
and Bad using Turbofect transfection reagent and protocol (#R531, Thermo Scientific, Rockford,
IL, USA). Site-specific mutants of HA-14-3-3ζ were produced using Agilent Quickchange kit
(Santa Clara, California, USA). U2OS and HEK-293T cells were transfected with smartpool
siRNA from Dharmafect (Thermo Scientific, Rockford, IL, USA) using RNAiMAX
Lipofectamine reagent and protocol (Invitrogen, Rockford, IL, USA).
Acetyl-proteomics and data analysis-Samples for acetyl-proteomics were generated by
solubilization of cellular proteins, tryptic digestion, enrichment of acetyl-lysine (Kac) peptides,
and LC-MS/MS analysis similar to previously described, with the exception that a pan-acetylK
antibody (#11786BK) from Cell Signaling Technologies was utilized for the IP (20). Care was
taken that the temperature not exceed 32°C throughout the procedure, to limit protein
carbamylation by Urea. Briefly, samples were solubilized in 50 mM Ammonium Bicarbonate
(AmBic, pH 8) containing 8 M Urea, then normalized to total protein content across all samples
using a Bradford assay (Bio-Rad, Inc). The samples were reduced with 10 mM dithiothreitol at
32°C for 1 hr, followed by alkylation with 40 mM iodoacetamide for 1 hr in the dark. Samples
were diluted to 1.8 M Urea with AmBic, then sequencing grade trypsin was added at a 1:25 w/w
ratio and digestion proceeded overnight at 32°C. Samples were acidified to 1% TFA, buffer
exchanged with Sep Pak C18 (Waters) and lyophilized to dryness. Peptides were resuspended in
IAP Buffer (Cell Signaling Technologies) and incubated with a 40 ul aliquot of PTMScan AcetylK enrichment kit (11786BK) at 4C overnight. Enriched peptides were eluted with 1% TFA for 10
minutes, dried in a speed-vac, and resuspended in 12 ul 1/2/97 v/v/v TFA/MeCN/water containing
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a total of 50 fmol ADH1_YEAST digest (Waters Corporation). LC-MS/MS analysis took place
on a nanoAcquity UPLC coupled via electrospray to a LTQ Orbitrap XL mass spectrometer
exactly as previously described (20). Database searching for peptide identifications utilized
Mascot v2.2 (Matrix Sciences), searching the Uniprot (‘reviewed’) database (www.uniprot.org)
with homo sapiens taxonomy, searching the data with 10 ppm precursor and 0.8 Da product ion
tolerance, and allowing for variable modifications deamidation (NQ), oxidation (M), and
acetylation (K). Quantitative data were processed in Rosetta Elucidator v3.3, allowing relative
quantification of all peptides identified in this dataset based on extracted ion chromatograms (peak
areas) and accurate-mass and retention time alignment.
Western blotting – HEK-293T and U2OS cells were plated in 10-cm dishes at 75%
confluency and transfected with HA-14-3-3ζ expression vector. Cells were trypsinized and plated
in up to six 10-cm dishes and allowed to grow for 36 hours. Drug treatments were applied at
various concentrations for 6–12 hours as indicated. Cells treated with siRNA knockdown were
transfected with HDAC6 siRNA 12 hours after 14-3-3ζ transfection and allowed to grow for 36
hours. Following drug treatment or siRNA transfection, cells were lysed in an ice-cold co-IP buffer
(10 mM HEPES pH 7.5, 150 mM KCl, 0.1% NP-40) containing a phosphatase inhibitor cocktail
(#88667 Pierce, Rockford, IL, USA), a protease inhibitor cocktail (#88665 Pierce, Rockford, IL,
USA), and a pan-HDAC inhibitor cocktail consisting of SAHA (10 μM), Tubacin (40 μM), and
Nicotinamide (50 μM; #72340 Sigma, St. Louis, MO, USA). Cell lysates were centrifuged at
21000xg for 10 minutes at 4C. Supernatant was incubated with 15 μL anti-HA agarose resin
(#26181, Pierce, Rockford, IL, USA) for 1.5 hours at 4C. Following several washes with buffer,
resin was boiled with SDS sample buffer (10% SDS, 30% glycerol, 0.7 M beta-mercaptoethanol,
0.15 M Tris, Bromophenol Blue). Samples were loaded and separated on 12% polyacrylamide
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gels run along side a Bluestain protein ladder (#P007, GoldBio, St. Louis, MO, USA). Western
blots were visualized on LI-COR Odyssey system (Lincoln, NE, USA).
Antibodies – Primary antibodies included: AS160 (#2447S), Atg9 (#13509S), Bad
(#9292S), Flag (#8146S), HDAC6 (#7612S), phospho-14-3-3ζ binding motif (#9601S), phosphoAS160 (Thr642, #4288S), and phospho-Bad (Ser112, #9291S) purchased from Cell Signaling
Technology (Beverly, MA, USA); 14-3-3ζ (sc-1019), Actin (sc-1616-R), HA (sc-7392), Kinesin
(sc-28538), and Liprin-β (sc-22876) purchased from Santa Cruz Biotechnology (Dallas, TX,
USA); Polyhistidine provided by Dr. Barry Willardson (Brigham Young University, Provo, Utah,
USA). Secondary antibodies purchased from LI-COR (Lincoln, NE, USA) included: Donkey anti
rabbit (#926-32213), goat anti mouse (#926-68070), donkey anti mouse (#926-32212), and goat
anti rabbit (#926-68071).
Ac-K49 and Ac-K120 antibody purification – Rabbit serum was prepared from animals
immunized with an acetylated K49 or K120 peptide sequence conjugated to KLH (Pocono Rabbit
Farm and Laboratory, Inc.). Ac-K49 polyclonal antibody was immuno-purified from serum using
acetylated K49 peptide as previously described (30). Briefly, biotinylated K49 peptide was bound
to streptavidin agarose (#20359, Thermo Scientific, Rockford, IL, USA) and incubated overnight
with rabbit serum diluted in buffer (150 mM Tris pH 7.5, 20 mM NaCl) (1:1) in order to deplete
serum of non-acetyl specific antibody. After incubation, serum was removed and transferred to
acetylated K49 peptide bound to streptavidin resin for overnight incubation. Acetylated K49 bound
resin was then washed twice with buffer. Acetyl-specific antibody was eluted off resin using
gravity fed elution (100 mM Glycine pH 2.8). Fractions were collected in neutralization buffer (1
M Tris pH 8.5) and tested for antibody titer. Ac-K120 antibody was produced as described above
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and purified on a protein-A resin, followed by elution with 100 mM Glycine (pH 2.8) into
neutralization buffer (above) to a final pH of 7.5.
In vitro acetylation assay – BL21-DE3 cells were transformed with pGEX-His-14-3-3ζ and
grown in LB broth with ampicillin (100 μg/mL). Once O.D. reached 0.6, cells were induced with
IPTG (1 mM) and allowed to express for 4 hours. Bacterial cells were pelleted, lysed in buffer (20
mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mg/mL
lysozyme) containing a protease inhibitor cocktail (#88665 Pierce, Rockford, IL, USA), and
treated with DNaseI (2.5 mg/mL). Cell lysate was centrifuged at 21000xg for 10 minutes at 4oC.
Supernatant was incubated with 150 μL of nickel resin (H-320-5, GoldBio, St. Louis, MO, USA)
for 4 hours at 4C. After washes with assay buffer (20 mM HEPES, 100 mM NaCl, pH 8.0), a
portion of the 14-3-3ζ resin (37.5 μL) was removed for control. Remaining resin (112.5 μL) was
incubated with recombinant p300 acetyltransferase enzyme (60 U; purchased from Enzo Life
Sciences, BML-SE451-0100) and acetyl-CoA (10 μM) in assay buffer for an hour at 37C.
Following washes, equal portions of the resin were incubated with recombinant HDAC6 enzyme
(60 U) alone or HDAC6 enzyme (60 U) with Tubacin (40 μM) for an hour at 37C. Following
additional washes, resin was boiled with SDS sample buffer and separated on a 12% SDS-PAGE
gel. Following gel transfer, the membrane was probed with acetyl-K49 antibody.
Gel filtration assay – HEK-293T cells were transfected with HA-14-3-3ζ WT or K49Q
mutant expression vector and allowed to express for 48 hours. Cells were then lysed by dounce
homogenization using hypotonic lysis buffer (20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1
mM EDTA, 1 mM EGTA, 1 mM DTT) containing a protease inhibitor cocktail (#88665 Pierce,
Rockford, IL, USA). 2.5 mg of total protein lysate was loaded onto a superdex 200 10/300 GL gel
filtration column running on an AKTA FPLC system (GE healthcare, Pittsburgh, PA, USA). Cell
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lysate was fractionated at a flow rate of 500 μL/min using hypotonic lysis buffer. 300 μL elution
fractions were collected and separated on a 12% SDS-PAGE gel. Following gel transfer,
membranes were probed for HA epitope.
Flow cytometry – HEK-293T cells were plated in 6-cm dishes at a confluency of 75%.
Cells were transfected with HA-14-3-3ζ WT or RR mutant expression plasmid. HEK-293T cells
were then trypsinized and plated in 6-well plates at 30% initial confluency and allowed to express
for 36 hours. Cells were treated with either vehicle or Tubacin (10 μM or 40 μM) for 24 hours.
Following treatment, the 6-well plates were prepared for flow cytometry analysis. Briefly, cells
were trypsinized and washed twice with cold PBS. Next, cells were resuspended in cold PBS
containing 0.2% FBS and 1 μg/ml propidium iodide. Cells were analyzed for cell death using BD
Facs Canto system.

RESULTS
14-3-3ζ expression is elevated in receptor-negative breast tumors, and high expression
correlates with decreased patient survival—Consistent with the role of 14-3-3ζ in driving multiple
oncogenic pathways, previous studies have demonstrated that 14-3-3ζ expression is increased in
several cancer types, including breast cancer (11,13,19). To acquire breast cancer subclass-specific
information on 14-3-3ζ, we analyzed 14-3-3ζ transcript levels from primary human breast tumors
available through The Cancer Genome Atlas (TCGA) database. We found elevated 14-3-3ζ
expression levels in the more aggressive basal, HER2-positive, and luminal B subtypes of breast
cancer compared to lower expression levels in the typically less aggressive luminal A tumors (Fig.
1A). In addition, we found that breast tumors that lack estrogen and progesterone receptors show
higher 14-3-3ζ transcript levels (Fig. 1B). Interestingly, given a previous study showing that 14-
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4 Figure 1. 14-3-3ζ expression is elevated in receptor-negative breast tumors, and high expression

correlates with decreased patient survival. (A) YWHAZ (14-3-3ζ) expression was analyzed in Basal
(n=94), HER2 (n=56), LumA (n=228), and LumB (n=123) breast cancer samples and expressed as Boxand-Whisker plots. P value was calculated by comparing all groups with the ANOVA test. (B) 14-3-3ζ
expression was analyzed in progesterone receptor (PR) positive (n=523), PR negative (n=252), estrogen
receptor (ER) positive (n=602), ER negative (n=176), HER2 positive (n=129), HER2 negative (n=429),
triple negative breast cancer (TNBC, n=85), and non-TNBC (n=468) data sets. Data are expressed in Boxand-Whisker plots. P values were calculated using standard two-sample t-test. (C) Kaplan Meier analysis
of 14-3-3ζ expression levels correlated with patient survival. Breast cancer patients whose tumors fell within
the highest (n=164) and lowest (n=163) quintiles of 14-3-3ζ expression were compared. Statistical
significance was calculated using the log-rank test. All data were derived from The Cancer Genome Atlas
(TCGA) database.

3-3ζ acts cooperatively with HER2 to drive growth and metastasis in breast cancer (10), we found
that 14-3-3ζ expression is higher in HER2-positive tumors (Fig. 1B). Finally, by comparing
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patients within the highest and lowest quintiles of 14-3-3ζ expression across all breast cancer
subtypes in the TCGA database, we found that high 14-3-3ζ expression is correlated with
decreased patient survival (Fig. 1C). Thus, both tumor expression data and our current
understanding of 14-3-3ζ-driven pro-growth and survival pathways support the notion of 14-3-3ζ
as a therapeutic target to disrupt a hub of oncogenic signaling.
Acetylated lysines within the 14-3-3ζ binding pocket and protein-protein interface—While
several groups have worked to develop inhibitors of 14-3-3ζ (reviewed in (21)), these efforts have

Figure 2. Analysis, we found that several lysines within the 14-3-3ζ binding pocket and proteinprotein interface were targets of acetylation. As shown in Figure 2A, which is derived from a published
crystal structure of 14-3-3ζ bound to c-Raf (2.2 Å resolution; (32)), two of these lysines, K49 and K120
were previously identified in a large-scale proteomics screen (33) and are posited to interact with the
negatively charged Ser/Thr phosphorylation of the binding partner. K49, in particular, is known to be
important for 14-3-3ζ interactions (34,35). K193 and K212 are located outside this binding pocket, but
within regions of 14-3-3ζ that may interface with the interacting partner.
5
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proven challenging at least partly due to difficulty in developing high-throughput screens for 143-3ζ activity (although recent progress has been made in this area (31)). This challenge motivated
us to look for other ways to manipulate 14-3-3ζ binding, potentially via 14-3-3ζ regulatory
mechanisms. Using immunoprecipitation with acetyl-lysine antibodies followed by LC-MS/MS
analysis, we found that several lysines within the 14-3-3ζ binding pocket and protein-protein
interface were targets of acetylation. As shown in Figure 2A, which is derived from a published
crystal structure of 14-3-3ζ bound to c-Raf (2.2 Å resolution; (32)), two of these lysines, K49 and
K120 were previously identified in a large-scale proteomics screen (33) and are posited to interact
with the negatively charged Ser/Thr phosphorylation of the binding partner. K49, in particular, is
known to be important for 14-3-3ζ interactions (34,35). K193 and K212 are located outside this
binding pocket, but within regions of 14-3-3ζ that may interface with the interacting partner.
Acetylation-mimicking mutations abolish 14-3-3ζ interactions—To estimate the impact of
each of these acetylations on 14-3-3ζ binding activity, we generated K-to-Q mutations, which
mimic the change in charge associated with acetylation. We assessed the binding activity of these
mutants by HA-14-3-3ζ overexpression/co-immunoprecipitation (co-IP) and western blotting for
several readily detectable 14-3-3ζ interacting proteins, including known interactors such as AS160,
Kinesin, and Bad as well as Liprin-β, which we recently identified in an interactomics screen (36)
(Fig. 3A). Both the K49Q and K120Q mutations blocked 14-3-3ζ interactions, with K49Q having
the most potent inhibitory effect (Fig. 3A). In contrast, we were unable to see any consistent effect
with the K193Q and K212Q mutations (Fig. 3A).
To examine the effect of the K49Q mutation on a larger scale, we performed gel filtration
chromatography with HEK-293T lysates expressing either HA-tagged WT 14-3-3ζ or the K49Q
mutant. Consistent with published reports showing 14-3-3ζ interacting with a wide range of
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proteins and protein complexes (37,38), we observed WT 14-3-3ζ across a broad size spectrum
ranging from 670 kDa to the 14-3-3ζ dimer near 60 kDa and the 14-3-3ζ monomer at 30 kDa (Fig.
3B). Strikingly, the Q substitution at K49 alone was sufficient to disrupt interactions with high
molecular complexes, as this mutant was found shifted into the dimer/monomer range (Fig. 3B).

6 Figure 3. Acetylation-mimicking mutations abolish 14-3-3ζ interactions. (A) HEK-293T cells were
transfected with WT or mutant forms of HA-tagged 14-3-3ζ plasmid expression vector (K to Q mutants at
each acetylated lysine residue). Cell lysates were immunoprecipitated with HA agarose resin and run on
12% SDS-PAGE for immunoblotting for Kinesin, AS160, Liprin-β (36), and Bad. Representative data of
at least three replicate experiments. (B) HEK-293T cells were transfected with WT or K49Q HA-tagged
14-3-3ζ and subjected to gel filtration. Eluted fractions were collected and run on separate 12% SDS-PAGE
for immunoblotting with HA (14-3-3ζ) antibody. Representative data of at least four replicate experiments.
Deacetylation-mimicking mutations rescue the loss of 14-3-3ζ interactions—To determine
whether the loss of 14-3-3ζ binding activity caused by the K49Q and K120Q substitutions was due
simply to a disruption of the charge as opposed to some other alteration, such as blocking another
lysine-targeted post-translational modification, we substituted arginine at K49 and K120 and
measured 14-3-3ζ interactions as in Fig. 3A. In addition to the interacting partners mentioned
above, we also measured 14-3-3ζ binding to Atg9, which we recently published as a new 14-3-3ζ
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binding partner (36). As shown in figure 4A-4B, the K49R/K120R double mutant effectively
restores 14-3-3ζ binding activity to at or near WT levels.

7 Figure 4. Deacetylation-mimicking mutations rescue the loss of 14-3-3ζ interactions. (A) HEK-293T

cells were transfected with WT or mutant forms of HA-tagged 14-3-3ζ plasmid expression vector (K to Q
mutants at K49 or K120, K to R double mutant at K49 and K120). Cell lysates were immunoprecipitated with
HA agarose resin and run on 12% SDS-PAGE for immunoblotting of the binding partners Kinesin, AS160,
Liprin-β, Bad, and Atg9 (36). Phosphorylation of 14-3-3ζ binding site of Bad (S112) was compared to total
Bad in lysate (overlay). Representative data of at least three replicate experiments. (B) Western blot data from
seven replicate experiments of panel A were quantified using LI-COR infrared band imaging. Relative
interaction values represent the quantified signal of interacting-protein divided by HA signal. P values
indicated by asterisk were calculated using two-sample T test and are as follows: Kinesin = 0.042; Liprin-β =
0.044; Bad = 0.041

As a measure of 14-3-3ζ binding, we assessed the activation status of Bad by monitoring
its phosphorylation at S112. The inhibitory phosphorylation of Bad at S112 and S136 leads to
14-3-3ζ binding (6), which maintains Bad inhibition likely by shielding the phosphorylations
from phosphatase activity. We observed an increase in S112 phosphorylation in the presence of
WT 14-3-3ζ. Consistent with the interaction data, this increase in S112 phosphorylation was lost
in cells expressing the K49Q and K120Q mutants, but recovered by expression of K49R/K120R
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(Fig. 4A; see phospho-Bad/Bad overlay). Based on these data and the estimated distance
between both K49 and K120 and the phosphate of the binding partner (~3 and ~6 angstroms,
respectively; Fig. 2), we posit that acetylation at these sites disrupts a positive-negative
electrostatic interaction between the primary amine of lysine and the phosphate that is important
for stabilizing the 14-3-3ζ-protein complex (35).
HDAC6 deacetylates 14-3-3ζ at K49 and K120—The strong inhibitory effect of charge
disruption at K49 and K120 suggests that modulating the enzymes that govern acetylation at these
sites may provide a means to inhibit 14-3-3ζ binding activity. Our attempts to detect acetylation at
these sites with pan-acetyl-lysine antibodies yielded inconsistent results. Therefore, we generated
site-specific acetyl antibodies to each lysine. Because the Q substitution at K49 had a slightly
stronger inhibitory effect on 14-3-3ζ than K120Q, we focused our initial efforts on K49. By
treating HEK-293T cells expressing HA-tagged 14-3-3ζ with a panel of deacetylase inhibitors, we
found that drugs targeting class I and II HDACs, including Trichostatin A (TSA) and
suberanilohydroxamic acid (SAHA), triggered an increase in K49 acetylation (Fig. 5A). In
contrast, sirtuin inhibitors showed inconsistent effects on K49 acetylation. EX-527, a Sirt1 and
Sirt2 inhibitor, triggered a marginal increase in acetylation, but Salermide, a different Sirt1/2
inhibitor, failed to stimulate such an increase.
Because 14-3-3ζ predominately localizes to the cytoplasm, and HDAC6 is one of the few
cytoplasmic HDACs targeted by TSA and SAHA, we reasoned that HDAC6 was a likely culprit.
Using the HDAC6-specific inhibitor Tubastatin A (39), we observed a robust increase in K49
acetylation (Fig. 5B). Importantly, mutation of K49 to arginine abolished the Tubastatin A-induced
increase in acetylation, indicating the specificity of the antibody (Fig. 5B, last lane). Likewise,
Tubacin, a structurally distinct HDAC6 inhibitor (40), also triggered K49 acetylation in the
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osteosarcoma cell line U2OS (Fig. 5C). Furthermore, acetylation peaked at 6 hours post-treatment

8 Figure 5. HDAC6 deacetylates 14-3-3ζ at K49 and K120. (A) HEK-293T cells were transfected with

WT HA-tagged 14-3-3ζ expression vector and treated with various HDAC inhibitor drugs (SAHA 10 μM,
Trichostatin A (TSA) 10 μM, Tubastatin A (TubA) 40 μM, Salermide 40 μM, and EX-527 40 μM) or
vehicle (DMSO) under normal conditions for 9 hours. Cell lysates were immunoprecipitated with HA resin
and run on 12% SDS-PAGE immunoblotting for Ac-K49 (green) and HA (14-3-3ζ, red). Representative
data of at least three replicate experiments.
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Cont. Figure 5. (B) HEK-293T cells overexpressing WT or K49R mutant HA-tagged 14-3-3ζ were
treated with Tubastatin A (40 μM) or vehicle for 9 hours followed by HA immunoprecipitation and
immunoblot as in Fig. 4A (exception: HA is in green channel, Ac-K49 is in red channel). Representative
data of at least four replicate experiments. (C) U2OS cells overexpressing WT HA-tagged 14-3-3ζ were
treated with Tubacin (30 μM) for 8 hours followed by HA immunoprecipitation and immunoblotting as
in Fig. 4A. Representative data of at least three replicate experiments. (D) HEK-293T cells overexpressing
WT HA-tagged 14-3-3ζ were treated with Tubacin (35 μM) or Tubastatin A (35 μM) in a 2-, 4-, 6-, and
8-hour time course followed by HA immunoprecipitation and immunoblotting as in Fig. 4A.
Representative data of at least three replicate experiments. (E) 8 hour HDAC6 inhibitor time points from
four replicate experiments of panel D were quantified. Relative acetylation signal is Acetyl-K49 signal
divided by HA signal. Bands were quantified by LI-COR infrared imaging. (F) HEK-293T cells
overexpressing WT HA-14-3-3ζ were transfected with HDAC6 siRNA (75 nM) or scrambled siRNA (75
nM). Cell lysates were HA immunoprecipitated and immunoblotted as in Fig. 5A. Representative data of
at least three replicate experiments. (G) Three replicate experiments from panel F were quantified as in
panel E. (H) Recombinant His-tagged 14-3-3ζ was expressed in BL21-DE3 E. coli and purified on a
nickel resin. Resin-bound 14-3-3ζ was incubated with p300 acetyltransferase followed by vehicle,
HDAC6 recombinant enzyme, or HDAC6 enzyme and Tubacin (40 μM). 14-3-3ζ was analyzed by 12%
SDS-PAGE and immunoblotting with Ac-K49 and His (14-3-3ζ). Representative data of at least three
replicate experiments. (I) MDA-MB-231 breast cancer cells were treated with Tubacin (30 μM) or vehicle
for 8 hours. Endogenous 14-3-3ζ was analyzed by resolving cell lysate (40 μg) using 12% SDS-PAGE
and immunoblotting with Ac-K120 (green), 14-3-3ζ (red), and Actin. Representative data of at least three
replicate experiments. (J) MDA-MB-231 breast cancer cells were treated as in Fig. 4G. Endogenous 143-3ζ was analyzed as in Fig. 4G. Representative data of at least three replicate experiments. (K) HEK293T cells overexpressing WT or K120R mutant HA-tagged 14-3-3ζ were treated with Tubacin (40 μM)
or vehicle for 9 hours followed by HA immunoprecipitation and immunoblotting with Ac-K120 (green)
and HA (red). Representative data of at least three replicate experiments.

for both drugs (Fig. 5D). Figure 5E shows the quantified data of the HDAC6 inhibitor-induced
increase in K49 acetylation from four experiments. To rule out potential off-target effects of drug
treatment, we confirmed that siRNA against HDAC6 induced K49 acetylation (Fig. 5F and G) and
recombinant HDAC6 was capable of deacetylating K49 in vitro (Fig. 5H).
Next, we asked whether we could detect acetylation of endogenous 14-3-3ζ. Consistent
with our previous results, treatment of the triple negative breast cancer line MDA-MB-231 with
Tubacin triggered acetylation of endogenous 14-3-3ζ at K49 (Fig. 5I). Given the proximity of K49
and K120 in the 3-dimensional structure of 14-3-3ζ, we suspected that both lysines were substrates
of HDAC6. Indeed, HDAC6 inhibition resulted in acetylation of K120, as detected on endogenous
14-3-3ζ in MDA-MB-231 cells (Fig. 5J) and immunoprecipitated HA-tagged 14-3-3ζ from HEK293T cells (Fig. 5K). As in Fig. 4B, the K120R mutant served as a specificity control for the acetyl37

K120 antibody (Fig. 5K, last lane). Taken together, these data suggest that HDAC6 deacetylates
K49 and K120 and thereby may regulate 14-3-3ζ binding activity.
Inhibition of HDAC6 triggers a loss of 14-3-3ζ interactions and an increase in cell death,
both of which are rescued by the K49R/K120R double mutant—Our data suggest a model in which
high HDAC6 activity promotes 14-3-3ζ binding activity by maintaining K49 and K120 in their
deacetylated states. Conversely, as suggested by data in Figure 5, HDAC6 inhibition allows a
progressive build up of acetylation (presumably catalyzed by an unidentified acetyl-transferase) at
these residues. To test whether this increase in acetylation induces a loss of 14-3-3ζ binding
activity, we chose to focus on the 14-3-3ζ-interacting proteins AS160 and Bad. AS160 is a RabGTPase activating protein involved in GLUT4 translocation to cell membranes. Once on the
membrane, GLUT4 serves as a major receptor for glucose uptake in breast, multiple myeloma and
other cancers (3-5). Phosphorylation of AS160 at T642 triggers the binding of 14-3-3 proteins (ζ
and other isoforms), which leads to AS160 activation and GLUT4 translocation (2,41). Bad is a
pro-apoptotic BH3-only protein that transduces an apoptotic signal to mitochondria in response to
various chemotherapeutics (6-9). Phoshorylation of Bad at S112, as well as S136, leads to 14-3-3
binding and Bad inhibition (6). Both of these proteins can be readily detected in overexpression/coIP experiments with 14-3-3ζ.
Using HEK-293T cells and FLAG-AS160 immunoprecipitation, we found that HDAC6
inhibition decreases AS160-14-3-3ζ binding (Fig. 6A, lanes 2–3). Importantly, the loss of AS16014-3-3ζ interaction was rescued by the K49R/K120R 14-3-3ζ mutant (Fig. 6A, lanes 4–5),
suggesting that acetylation is the key event triggering disruption of the complex. We also
performed the converse immunoprecipitation experiment with HA-14-3-3ζ and Bad. Consistent
with data in Figure 6A, inhibition of HDAC6 triggers a decrease in the 14-3-3ζ-Bad interaction,
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which is rescued by the K49R/K120R mutant (Fig. 6B). Furthermore, as shown in Figures 6C and

9 Figure 6. Inhibition of HDAC6 triggers a loss of 14-3-3ζ interactions and an increase in cell death,
both of which are rescued by the K49R/K120R double mutant. (A) HEK-293T cells were co-transfected
with WT Flag-tagged AS160 expression plasmid along with either WT HA-tagged 14-3-3ζ, or
K49R/K120R (RR) double mutant expression plasmid, followed by treatment with Tubacin (30 μM) or
vehicle for 6 hours. Cell lysates were immunoprecipitated using Flag agarose and run on 12% SDS-PAGE
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Cont. Figure 6. for immunoblotting with HA (14-3-3ζ), pT642 (phosphothreonine642), and Flag
(AS160). Representative data of at least three replicate experiments. (B) HEK-293T cells were cotransfected with Bad expression plasmid along with either WT HA-tagged 14-3-3ζ, or K49R/K120R (RR)
double mutant expression plasmid, followed by treatment with Tubacin (30 μM) or vehicle for 9
hours. Cell lysates were immunoprecipitated using HA agarose and run on 12% SDS-PAGE for
immunoblotting with Bad and HA (14-3-3ζ). Cell lysate was immunoblotted with pS112
(phosphoserine112). Representative data of at least three replicate experiments. (C) HEK-293T cells were
transfected with WT Flag-tagged AS160 expression plasmid or mock followed by treatment with Tubacin
(40 μM) or vehicle for 6 hours. Cell lysates were immunoprecipitated using Flag agarose and run on 12%
SDS-PAGE for immunoblotting with 14-3-3ζ and Flag (AS160). Representative data of at least four
replicate experiments. (D) HEK-293T cells were transfected with WT HA-tagged Atg9 expression
plasmid or mock followed by treatment with Tubacin (40 μM) or vehicle for 6 hours. Cell lysates were
immunoprecipitated using HA agarose and run on 12% SDS-PAGE for immunobloting with 14-3-3ζ and
HA (Atg9). Representative data of at least four replicate experiments. (E) HEK-293T cells overexpressing
either WT 14-3-3ζ, K49R/K120R (RR) double mutant 14-3-3ζ, or mock transfection were treated with
Tubacin (10 μM, 40 μM) or vehicle for 48 hours. Cell death was measured by PI staining and flow
cytometry. Data presented as light microscope pictures (scale bar = 250 μm), or (F) Flow cytometry dot
plots, or (G) Bar graph (mean±SEM, n=3, p-value=0.029). P value was calculated using two-sample T
test. Inset is a immunoblot comparing expression of WT or RR mutant 14-3-3ζ. Cell lysates were analyzed
via 12% SDS-PAGE and immunoblot. Membrane was probed for HA (14-3-3ζ) and actin.

which is rescued by the K49R/K120R mutant (Fig. 6B). Furthermore, as shown in Figures 6C and
6D, HDAC6 inhibition effectively dissociates endogenous 14-3-3ζ from overexpressed interacting
partners AS160 and Atg9.
A critical function of 14-3-3 proteins is their ability to protect phosphorylations from
removal by phosphatases. For example, 14-3-3 binding to an inhibitory phosphorylation on Cdc25
protects it from protein phosphatase-1 activity, thereby preventing Cdc25 activation and entry into
M phase (42). Thus, we reasoned that forcing disruption of 14-3-3ζ via K49/K120 acetylation
should lead to dephosphorylation of the interacting partner. Indeed, phosphorylation of AS160 at
T642 and Bad at S112 tracked with 14-3-3ζ binding, showing decreased phosphorylation in cells
treated with HDAC6 inhibitor, and more importantly, a recovery of phosphorylation (albeit only a
marginal recovery with AS160) in the presence of the K49R/K120R mutant despite HDAC6
inhibition (Fig. 6A and 6B, see overlay images).
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HDAC6 inhibition enhances stress-induced cell death, and HDAC6 inhibitors are currently
being evaluated as potential therapeutics in cancer (28,43). HDAC6 has only a few bonafide
substrates, including its best characterized substrate tubulin, as well as HSP90, cortactin and
MSH2 (43,44). To test the role of 14-3-3ζ acetylation in the toxicity of HDAC6 inhibition, we
analyzed the cytoprotective effect of both WT 14-3-3ζ and the K49R/K120R mutant (compared to
mock controls) against HDAC6 inhibitor-induced cell death. Although the non-acetylatable
mutant was unable to completely suppress cell death (supporting the involvement of other HDAC6
substrates), it showed a significantly enhanced cytoprotective effect compared to WT 14-3-3ζ
(Figs. 6E–G). These data suggest that inhibitory acetylation of 14-3-3ζ contributes to HDAC6
inhibitor-induced cell death. Based on these results, we posit that the exploitation of 14-3-3ζ
pathways with combination therapies may enhance the anti-tumor effect of HDAC6 inhibitors.

DISCUSSION
As a phospho-binding protein, 14-3-3ζ has been implicated in numerous pro-growth
pathways, and both in vitro and in vivo data point toward its function as an oncogene (reviewed in
(13)). We show here a new and potentially exploitable mechanism of 14-3-3ζ control by HDAC6.
Specifically, we demonstrate that 14-3-3ζ can be suppressed by HDAC6 inhibition and consequent
acetylation of K49 and K120, which sit within the 14-3-3ζ binding pocket. These data raise several
questions addressed below.
The position of K49 and K120 within the 14-3-3ζ binding pocket raises the question of
how acetylation occurs if the residues are buried between 14-3-3ζ and the interacting partner.
Since 14-3-3ζ exists in equilibrium between bound and unbound states, we favor the idea that the
unbound “free” pool of 14-3-3ζ is subjected to deacetylation/acetylation. This idea is supported by
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our unpublished in vitro experiments in which we could only acetylate recombinant 14-3-3ζ (using
the p300 catalytic domain as in Fig. 5H) when in the unbound form. Conversely, incubation of 143-3ζ with a purified interacting partner prevented acetylation, suggesting that lysines within the
binding pocket may be inaccessible to KAT activity when 14-3-3ζ is in a bound complex. In this
model, HDAC6 inhibition and acetylation of 14-3-3ζ simply shift the bound-to-unbound
equilibrium, increasing the pool of unbound 14-3-3ζ (Fig. 7).

10 Figure 7. HDAC6 maintains 14-3-3ζ (shown as a dimer) binding activity by deacetylating K49 and

K120 within the 14-3-3ζ binding pocket. Inhibition of HDAC6 leads to 14-3-3ζ acetylation and loss of 143-3ζ binding activity. Acetylation-induced dissociation of 14-3-3ζ interactions (e.g., with Bad and AS160)
results in a loss of pro-growth signaling. The KAT that acetylates K49 and K120 is unknown.

Another question raised by these data is whether HDAC6 inhibition and consequent
acetylation of K49 result in the global loss of 14-3-3ζ interacting partners. We suspect that this is
not the case given the vast array of 14-3-3ζ interacting partners (37) and the only partially
overlapping localization of HDAC6 and 14-3-3ζ. Thus, it seems more likely that the various pools
of 14-3-3ζ (e.g., nuclear, cytosolic, membrane-associated, etc.) may be regulated by different
KATs and KDACs. Notably, in a previous study using an unbiased biotin-switch proteomics
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approach in Xenopus eggs, we identified 14-3-3ζ as one of several putative substrates of Sirt1 (14).
However, as shown in Figure 5A, we observed a very minor increase in K49 acetylation with EX527 (a Sirt1 inhibitor) when compared to HDAC6 inhibition, which had the most robust effect in
human cell lines. In future studies, it will be important to identify the subset of 14-3-3ζ interacting
partners affected by HDAC6 inhibition as well as other KDACs (and KATs) that might regulate
acetylation at K49 in different cellular compartments.
One compartment in which HDAC6 and 14-3-3ζ are likely to be intertwined is in the
cytoskeletal and microtubule network. A key pro-survival function of HDAC6 is to recruit
misfolded proteins to microtubule-associated dynein motor complexes for transport to
aggresomes, which alleviates the toxic accumulation of misfolded proteins in cells (45-48).
Interestingly, 14-3-3 has recently been implicated in aggresome formation (49). Specifically, 143-3 proteins have been shown to interact with and promote the association of the dynein motor
complex with the Bcl-2-associate athanogene 3 (BAG3), a co-chaperone protein that helps target
misfolded proteins to aggresomes (49). Thus, the deacetylation of 14-3-3ζ and consequent
maintenance of its binding activity may be part of the mechanism of HDAC6-mediated aggresome
formation. Our observation that acetylation-refractory mutants of 14-3-3ζ protect cells from
HDAC6 inhibitors is consistent with this idea (Fig. 6E–G). HDAC6 and 14-3-3ζ also associate
with tau (50,51), a microtubule-associated protein involved in neurodegeneration. 14-3-3ζ binding
to tau promotes tau hyperphosphorylation and is implicated in the formation of toxic tau lesions in
Alzheimer’s disease brains (50,52). In future studies, it will be important to determine the role
that HDAC6 plays in regulating these and other functions of 14-3-3ζ.
The strong inhibitory effect of acetylation on 14-3-3ζ binding raises the question of why
and when would these acetylations occur physiologically. Under high growth conditions, HDAC6
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activity appears to stay consistently high, which would lead to a low stoichiometry of acetylation.
In turn, active 14-3-3ζ would reinforce pro-growth signaling. Indeed, our LC-MS/MS analysis of
total 14-3-3ζ immunoprecipitated from cells indicates a low baseline level of acetylation under
normal growth conditions (Andersen, unpublished). A study by Xiaohong Zhang and colleagues
found that HDAC6 is phosphorylated by ERK, which increases HDAC6 activity and promotes cell
motility (53). Thus we speculate that the acetylation status of 14-3-3ζ is dictated by pro-growth
signaling. For example, growth factor withdrawal may lead to increased 14-3-3ζ acetylation as a
result of lower ERK-mediated HDAC6 activity. This seems likely given that 14-3-3ζ promotes
numerous cell growth pathways and therefore would need to be shut off during quiescence.
In summary, our data highlight a novel role for HDAC6 in the regulation of 14-3-3ζ. Going
forward, it will be critical to determine the full impact of HDAC6 inhibition on the vast network
of 14-3-3ζ interactions, and whether other 14-3-3 family members are similarly regulated, as this
may illuminate novel combination strategies to enhance the efficacy of HDAC6 inhibitors.
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CHAPTER 4: DISCUSSION
Lysine acetylation has become an important topic in cytosolic cellular regulation. The utility of
specific and non-specific inhibition of proper acetylation regulation in cancer cells is being
aggressively explored in clinical trials. We wanted to investigate how breast cancer cells changed
their cytosolic acetylation under the physiologically relevant metabolic stress of hypoxia. We
hoped this would give us some insight into which acetylation(s) may be important for a tumor
cell’s ability to cope with a lethal metabolic environment. Given the ability of tumor cells to
survive hypoxia, we also sought to determine whether widespread deregulation of acetylation via
small molecule inhibitors would promote cell death in hypoxia. This would lend more weight of
evidence to the use of such chemotherapies against tumor cells.
Our finding indicate that breast tumor cells, which are very adept at hypoxia survival, are
able to tightly regulate their acetylation(s) from normoxia to hypoxia. The fact that hypoxia didn’t
cause as big of a change to acetylation status for the tumor cells could be due to tumor cells being
pre-adapted to survival under such conditions. These cells may have a PTM preset for metabolic
stress and are therefore much more likely to survive the rapid/transient hypoxia that they are
exposed to. If this is the case, tumor cells would be especially susceptible to acetylation
deregulation via small molecule inhibitors. Our findings would lend support to this hypothesis.
Using a general HDAC inhibitor we were able to show tumor cells being sensitized to hypoxiainduced cell death. The specific lysine residues which are more critical to the survival of a tumor
cell must be investigated further. If we can identify important lysine residues on pro-survival
protein targets, we can then find how they are regulated thus giving us the ability to target more
critical acetylation pathways in tumor cells.
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Using general HDAC inhibitors which disrupt cellular acetylation has been a useful
approach. Using a specific HDAC inhibitor could have a similar sensitizing impact on tumor cells
without causing undesired off-target effects. This of course would require investigation into which
acetylation regulating enzymes are more critical to tumor cell survival. To investigate this we used
a siRNA knockdown approach to determine which protein targets were more necessary to hypoxia
survival. Our date show several targets which cause a decreased ability to survive hypoxia when
depleted from cells. HDAC6, being one of those targets, has been used to develop specific
inhibitors for chemotherapy drug trials. Indeed knockdown of HDAC6 alone showed an increase
in cell death in hypoxia resistant tumor cells, demonstrating the usefulness of HDAC6 as a drug
target.
While understanding that HDAC6 is critical to tumor cell survival is necessary to designing
specific drug treatments, It is also very useful to understand which targets of HDAC6 would help
account for its pro-survival activity. To date very few substrates of HDAC6 have been found. If
we can find pro-survival targets of HDAC6 then there is the possibility of multi-pathway drug
designing, using one drug to inhibit HDAC6 and another to inhibit another pathway which could
compound the effectiveness of the both drugs. Fortunately we identified a substrate of HDAC6
which is critical to the survival of tumor cells. We identified lysine residues of 14-3-3ζ which were
acetylated, some of which were critical to the function of the protein. We then used a screening
approach to identify the HDAC that regulated these critical acetylation events. Using various
techniques and approaches, we were able to determine that HDAC6 regulates 14-3-3ζ via
deacetylation of lysine 49 and 120. This information sheds light on the various pathways which
HDAC6 may be regulating through 14-3-3ζ. Further work must be done to identify which 14-3-3ζ
pathways are disrupted through HDAC6 inhibition. The pathways that we identified in our study
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are a good starting point for further investigation. If the disruption of 14-3-3ζ interaction with
AS160 or Bad can be recapitulated in vivo we may be able to combine HDAC6 inhibition with a
pro-apoptotic Bad mimetic or a chemotherapy which targets glucose utilization. These are just two
of the many 14-3-3ζ mediated pathways which have potential for combinatorial drug therapy.
Another question is raised by our work is which acetyltransferase is responsible for the
addition of acetyl groups to 14-3-3ζ? This question must be addressed to gain a full understanding
of how 14-3-3ζ is regulated via acetylation. Will we see a change in acetylation status of 14-3-3ζ
if we inhibit acetyltransferase activity? We may not see a change in acetylation status if it is
controlled primarily through HDAC6 activity. In other words, if the acetylation is held at a very
low level by HDAC6 we may not see any difference after actyeltransferase inhibition. This could
mean that some acetylation events may necessarily be held in tight control to prevent cell death.
These questions must be answered not only for how 14-3-3ζ is regulated, but how acetylation
events regulate other critical proteins in the tumor cell.
The field of non-histone acetylation has become important to the understanding of how
cells are regulated. Much more must be done to further our understanding of how tumor cells use
acetylation to become tumorigenic and survive normally lethal environments. The tools of mass
spectrometry and immune-detection have come a long way, though more needs to be done to be
able to ask critical question in the field of acetylation.
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